Serina Therapeutics, Inc.
SER · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $56 | $3,153 | $500 | $3,039 |
| % Growth | -98.2% | 530.6% | -83.5% | – |
| Cost of Goods Sold | $194 | $90 | $0 | $0 |
| Gross Profit | -$138 | $3,063 | $500 | $3,039 |
| % Margin | -246.4% | 97.1% | 100% | 100% |
| R&D Expenses | $7,480 | $2,388 | $1,573 | $3,799 |
| G&A Expenses | $0 | $3,894 | $1,289 | $1,298 |
| SG&A Expenses | $9,430 | $3,894 | $1,289 | $1,298 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$90 | -$92 | -$426 |
| Operating Expenses | $16,910 | $6,192 | $2,770 | $4,671 |
| Operating Income | -$17,048 | -$3,129 | -$2,270 | -$1,632 |
| % Margin | -30,442.9% | -99.2% | -454.1% | -53.7% |
| Other Income/Exp. Net | $5,841 | $8,398 | -$412 | $367 |
| Pre-Tax Income | -$11,207 | $5,269 | -$2,682 | -$1,265 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11,141 | $5,269 | -$2,682 | -$1,265 |
| % Margin | -19,894.6% | 167.1% | -536.4% | -41.6% |
| EPS | -1.51 | 0.63 | -2.49 | -8.05 |
| % Growth | -339.7% | 125.3% | 69.1% | – |
| EPS Diluted | -1.51 | 0.63 | -2.49 | -8.05 |
| Weighted Avg Shares Out | 7,359 | 8,414 | 1,079 | 1,077 |
| Weighted Avg Shares Out Dil | 7,359 | 8,414 | 1,079 | 1,077 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $2 | $11 |
| Interest Expense | $526 | $558 | $16 | $3 |
| Depreciation & Amortization | $194 | $90 | $61 | $33 |
| EBITDA | -$10,487 | $5,917 | -$2,605 | -$1,228 |
| % Margin | -18,726.8% | 187.7% | -521% | -40.4% |